Mannheim

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in … Ended recruitment
  2023-505812-39-00 5 2020-08-28 HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
• An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat … Ended recruitment
  2023-503421-19-00 5 2020-08-26 Urothelial cancer
• Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Ended recruitment
  2024-512961-15-00 5 2020-08-05 Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
• Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica … Ended recruitment
  2023-509394-23-00 5 2020-06-12 Stage II melanoma arising from a primary cutaneous site after surgery
• A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES). Ended recruitment
  2023-510455-28-00 5 2020-06-10 Hypereosinophilic Syndrome (HES)
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined … Ended recruitment
  2024-511577-29-01 5 2020-03-13 intermediate and high-risk rectal cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended recruitment
  2022-500674-34-00 4 2019-11-04 Marginal Zone Lymphoma
• A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended recruitment
  2024-510887-22-00 5 2019-09-30 Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
• Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended recruitment
  2022-500584-12-00 4 2019-09-11 Waldenström’s Macroglobulinemia
• Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended recruitment
  2024-515375-35-00 4 2019-08-26 Untreated patients with higher risk MDS and oligoblastic AML eligible
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• A Study of Avapritinib in Patients with Indolent and Systemic Mastocytosis Ended recruitment
  2024-512585-34-00 4 2019-02-27 Indolent Systemic Mastocytosis (ISM)
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen … Ended recruitment
  2023-510015-19-00 5 2019-02-11 Patients with histologically or cytologically documented muscle-invasi
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Bas … Ended recruitment
  2024-516662-11-00 5 2018-11-23 Ovarian epithelial cancer
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended recruitment
  2024-514945-12-00 10 2018-09-03 locally advanced resectable adenocarcinoma of the oesophagogastric jun
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended recruitment
  2024-517476-38-00 4 2018-05-14 Marginal Zone Lymphoma
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia

Showing 241–264 of 355 trials